A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.

Patient navigation services increased the rates of breast, cervical, and colorectal cancer 6-fold amongst women living in rural communities.

Yelena Shames, MSA, ACNP-BC, CNRN, discusses when immune checkpoint inhibitor treatment should be paused because of laboratory abnormalities.

The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.

Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.

At the 48th Annual Oncology Nursing Society Congress, nurses shared how they improved travel nurse orientation at their institution.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.

Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations.

The FDA has approved avapritinib for the treatment of patients with indolent systemic mastocytosis.

Elizabeth R. Cullen, MSN, ARNP, provides an overview of avasopasem manganese and its potential role in reducing severe oral mucositis for patients undergoing radiotherapy.

Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.

The FDA has issued a complete response letter for vic-trastuzumab duocarmazine.

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.

The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.

Cabozantinib, in combination with nivolumab and ipilimumab, improved progression-free survival in patients with advanced renal cell carcinoma, but the rate of grade 3/4 adverse events was 79%.

Tia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Seth Eisenberg, ASN, RN, OCN, BMTCN, discusses his research comparing plastic-backed pads and the Splashblocker.

Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP, and Rosaleen Bloom, PhD, APRN, ACNS-BC, AOCNS, discuss the financial stressors that face patients undergoing radiation.

Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.

Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.